Cigna group director sells shares worth over $181,000 By Investing.com

Granger Elder, a director at Cigna Group (NYSE:CI), recently engaged in transactions involving the company’s stock, according to a new SEC filing. On June 17, Elder sold 547 shares of Cigna Group at a price range of $331.38, culminating in a total transaction value exceeding $181,000.

The transaction was executed under a Rule 10b5-1 trading plan, which was established on March 13, 2024. Such plans allow company insiders to set up a predetermined schedule for buying and selling securities to avoid accusations of insider trading.

Additionally, on the same date, Elder acquired the same number of shares, 547, at a price of $175.0938 per share. This buy transaction amounted to a total of approximately $95,776.

It’s worth noting that these transactions do not necessarily indicate a change in the company’s fundamentals or Elder’s long-term view of the company’s prospects. The sale and purchase of shares are common practices among corporate executives and can be influenced by a variety of factors, including personal financial planning and diversification strategies.

Following these transactions, Elder’s direct ownership in Cigna Group’s common stock has adjusted, reflecting the new total of shares held after the reported date.

Investors and stakeholders often monitor insider trading activities as they can provide insights into how the company’s top executives view the stock’s value and future performance. However, these transactions should not be used in isolation to make investment decisions.

Cigna Group, with its standard industrial classification in hospital and medical service plans, continues to be a significant player in the healthcare sector. The company’s stock performance and insider trading activities are closely watched by the market for indications of the company’s operational and financial health.

In other recent news, Cigna Corporation (NYSE:) has been the focus of several analyst upgrades following strong first-quarter results. Jefferies has raised its price target for Cigna from $385 to $407, citing the company’s outperformance in its medical loss ratio. Oppenheimer also increased its price target from $370 to $400, following robust first-quarter results and a solid Medical Cost Ratio. Cantor Fitzgerald boosted its price target to $400 from $384, reflecting confidence in the earnings growth of Evernorth, Cigna’s health services segment. RBC Capital Markets nudged its price target slightly to $384 from $383 in response to Cigna’s robust first-quarter financial results.

Cigna’s first quarter of 2024 saw total revenue reaching $57.3 billion and adjusted earnings per share (EPS) climbing to $6.47. This strong performance led to the company raising its full-year adjusted EPS guidance to a minimum of $28.40. The growth was driven by significant increases in their Specialty businesses within Evernorth and the Cigna Healthcare segment.

These are recent developments which have seen Cigna’s stock targets being revised upwards by various analyst firms. However, potential risks include larger-than-expected employer give-backs due to contractual arrangements, higher initial costs related to the launch of the CNC contract, and challenges in further integrating Evernorth products into the commercial book. Despite these challenges, analyst firms maintain a positive outlook for Cigna’s future performance.

InvestingPro Insights

In light of the recent insider trading activity at Cigna Group (NYSE:CI), it’s essential to consider the broader financial metrics and trends that may impact the company’s stock performance. According to InvestingPro, Cigna’s management has been actively involved in share buybacks, a sign that could be interpreted as confidence in the company’s valuation and future prospects (InvestingPro Tip #0). Additionally, Cigna has a history of rewarding its shareholders, having raised its dividend for 3 consecutive years (InvestingPro Tip #1), which may interest income-focused investors.

On the financial front, Cigna’s market capitalization stands at a robust $95.11 billion, reflecting the company’s significant presence in the healthcare providers and services industry. The company boasts a Price/Earnings (P/E) ratio of 18.22 for the last twelve months as of Q1 2024, which compares favorably to the industry average and suggests a potentially attractive valuation for investors considering long-term positions. Moreover, Cigna’s revenue growth has been impressive, with an 11.67% increase over the last twelve months as of Q1 2024, indicative of the company’s ability to expand its revenue streams in a competitive sector.

For those considering investment in Cigna Group, there are additional InvestingPro Tips available, including insights into the company’s free cash flow yield, low price volatility, and trading at a low revenue valuation multiple. With these considerations in mind, investors can make more informed decisions about the company’s stock. To explore these tips further, consider subscribing to InvestingPro with an additional 10% off a yearly or biyearly Pro and Pro+ subscription using the coupon code PRONEWS24. There are 11 additional tips listed in InvestingPro that could be valuable to your investment research.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.